3 assets in Ureter Neoplasm

Therapeutic assets addressing Ureter Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Ureter Neoplasm	Eli Lilly and Company	P2	BB (68)
Pembrolizumab Ureter Neoplasm	Eli Lilly and Company	P1/2	CCC (54)
Loxo-435 Ureter Neoplasm	Eli Lilly and Company	P1	CC (43)